Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical implications of variable antiarrhythmic drug metabolism.

Pharmacogenetics - 1 Feb 1992

Buchert E, Woosley R L

Abstract excerpt

Due to their narrow therapeutic indices, antiarrhythmic drugs have a great potential for adverse outcome. This is amplified by extreme inter-individual variability in their disposition and their pharmacological actions. Genetically determined inter-individual differences in metabolism account for...

Topics

Anti-Arrhythmia Agents
Arrhythmias, Cardiac
Cytochrome P-450 CYP2D6
Cytochrome P-450 Enzyme System
Genetic Variation
Genotype
Humans
Kidney
Liver
Mixed Function Oxygenases

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 1302039
DOI: 10.1097/00008571-199202000-00002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-1302039-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical implications of variable antiarrhythmic drug metabolism.PMID 1302039Read ↗

Pharmacogenetics and drug-induced arrhythmiasSemantic proximity Read ↗

[Pharmacogenetic aspects of antiarrhythmic drug therapy].Semantic proximity Read ↗

The genetics of pro-arrhythmic adverse drug reactions.Semantic proximity Read ↗

Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol.Semantic proximity Read ↗

The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone.Semantic proximity Read ↗

[Use of Pharmacogenetic Information for Therapeutic Drug Monitoring of an Antiarrhythmic Drug].Semantic proximity Read ↗

Understanding variation in metoprolol response: CYP2D6, drug interactions, and phenoconversion.Semantic proximity Read ↗

Genetic basis of drug-induced arrhythmias.Semantic proximity Read ↗

Genetically determined adverse drug reactions involving metabolism.Semantic proximity Read ↗

Genetic Variation of Hepatic Enzymes Influence on β-Blocker Dose in Patients With Reduced Ejection Fraction Heart Failure.Semantic proximity Read ↗

Clinical consequences of polymorphic drug oxidation.Semantic proximity Read ↗

Complete Heart Block Secondary to Flecainide Toxicity: Is It Time for CYP2D6 Genotype Testing?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.